0000950170-24-037241.txt : 20240327 0000950170-24-037241.hdr.sgml : 20240327 20240327163016 ACCESSION NUMBER: 0000950170-24-037241 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kastelein Johannes Jacob Pieter CENTRAL INDEX KEY: 0002000389 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41562 FILM NUMBER: 24791227 MAIL ADDRESS: STREET 1: C/O NEWAMSTERDAM PHARMA COMPANY N.V. STREET 2: GOOIMEER 2-35 CITY: NAARDEN STATE: P7 ZIP: 1411 DC ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NewAmsterdam Pharma Co N.V. CENTRAL INDEX KEY: 0001936258 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC BUSINESS PHONE: 35 206 2971 MAIL ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC FORMER COMPANY: FORMER CONFORMED NAME: NewAmsterdam Pharma Co B.V. DATE OF NAME CHANGE: 20220701 4 1 ownership.xml 4 X0508 4 2024-03-26 0001936258 NewAmsterdam Pharma Co N.V. NAMS 0002000389 Kastelein Johannes Jacob Pieter C/O NEWAMSTERDAM PHARMA COMPANY N.V. GOOIMEER 2-35 NAARDEN P7 1411 DC NETHERLANDS true true false false Chief Scientific Officer false Ordinary Shares 2024-03-26 4 M false 201673 A 201673 I See footnote Ordinary Shares 2024-03-26 4 F false 11197 22.72 D 190476 I See footnote Ordinary Shares 2024-03-26 4 S false 190476 21.50 D 0 I See footnote Option (right to buy) 2024-03-26 4 M false 201673 0.00 D 2031-07-06 Ordinary Shares 201673 970229 I See footnote The exercise price of the option is EUR 1.16392. The Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the Ordinary Shares held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the Ordinary Shares held on behalf of Futurum. Represents Ordinary Shares that were withheld to satisfy the exercise price due upon the exercise of the options. These shares were sold in multiple transactions at a price of $21.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The Ordinary Shares were sold by the Reporting Person pursuant to an exemption in a lock-up agreement, dated February 12, 2024, in order to satisfy certain tax liabilities. The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the securities held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the securities held on behalf of Futurum. /s/ Louise Kooij by Power of Attorney from Johannes Jacob Pieter Kastelein 2024-03-27